Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON (Nasdaq: IMNN) will host a Third Quarter 2025 Financial Results and Business Update conference call on Thursday, November 13, 2025 at 11:00 a.m. ET. The company will discuss results for the quarter ended September 30, 2025 and provide an update on its Phase 3 clinical development program for IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.
Dial-in numbers are provided for North America and international participants, a live webcast will be available, and the call will be archived for replay through November 27, 2025 with an audio replay accessible for 90 days.
IMUNON (NASDAQ: IMNN) will host an in-person and virtual R&D Day in New York City on November 10, 2025 at the Harvard Club, starting at 8:00 a.m. ET.
The program will provide updates on the pivotal Phase 3 OVATION 3 study and Phase 2 MRD trial for IMNN-001, featuring presentations from ovarian cancer clinicians, Phase 3 investigators, statistical experts, and IMUNON management on safety, translational data, trial design and IMNN-001’s potential role in advanced ovarian cancer. The event includes a live Q&A and networking with speakers.
Registration is available for in-person or virtual attendance via RSVP.
IMUNON (Nasdaq: IMNN) will present a trials-in-progress poster on its pivotal Phase 3 OVATION 3 trial of IMNN-001 at the International Gynecologic Cancer Society Annual Global Meeting, Nov 5-7, 2025 in Cape Town.
IMNN-001 is a DNA-mediated IL-12 plasmid delivered by nanoparticle (TheraPlas platform). The company treated the first patient in July 2025, has activated 4 sites, and is considering up to 46 additional sites to accelerate enrollment. The same TiP poster was also accepted at ESMO 2025.
Poster: "OVATION-3: A randomized phase III trial..." Presenting author: Douglas V. Faller, M.D., Ph.D. Poster number: TP014/#750.
IMUNON (Nasdaq: IMNN) will present new translational data from the Phase 2 OVATION 2 study of IMNN-001 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on November 7, 2025 (Poster #1165, 12:15–1:45 PM ET).
IMNN-001 is a DNA-encoded IL-12 therapy using the TheraPlas® nanoparticle delivery platform. The company says OVATION 2 showed a clinically effective response in newly diagnosed advanced (stage IIIC/IV) epithelial ovarian cancer, including reported benefits in progression-free survival and overall survival, increases in key anti-cancer cytokines, and modulation of immune cell populations (CD8+ T cells, myeloid dendritic cells). IMNN-001 is advancing into the pivotal OVATION 3 Phase 3 trial per plan.
IMUNON (Nasdaq: IMNN) will host an R&D Day for investors on November 10, 2025 at the Harvard Club in New York City, starting at 8:00 a.m. ET.
The program will provide updates on the pivotal Phase 3 OVATION 3 study of IMNN-001 and a Phase 2 MRD trial, featuring presentations from ovarian cancer clinical leaders, Phase 3 investigators, statistical experts and IMUNON management. Presentations will cover safety, translational insights, trial design probability of success, and an OVATION 3 trial update, followed by a live Q&A and networking.
IMUNON (Nasdaq: IMNN) announced oral presentations of PlaCCine® DNA vaccine proof-of-concept data and IMNN-101 clinical results at two vaccine conferences: Oct 23, 2025 (International Vaccines Congress, Orlando) and Nov 6, 2025 (International Conference on Vaccine Research and Development, Boston).
IMNN reported positive six-month Phase 1 data showing better durability versus mRNA after a single dose targeting SARS-CoV-2 Omicron XBB1.5, with up to a 3-fold median increase in serum neutralizing antibody titers at six months and stronger responses in the 2.0 mg and 1.0 mg cohorts. IMNN-101 was safe and well tolerated with no serious adverse effects. The company is seeking strategic partners to advance PlaCCine commercialization, highlighting durability, temperature stability, and scalable manufacturing.
IMUNON (Nasdaq: IMNN) will present a trials-in-progress poster on its pivotal Phase 3 OVATION 3 study of IMNN-001 at the European Society for Medical Oncology (ESMO) Congress, October 17–21, 2025 in Berlin.
IMNN-001 is an IL-12 DNA plasmid delivered in a nanoparticle to elicit local tumor immune responses. The company announced the first patient treated in July 2025, has activated 4 sites, and is considering up to 46 additional sites to accelerate enrollment. The poster (No. 1234eTiP) will be presented by Dr. Premal H. Thaker and posted on IMUNON’s Scientific Presentations page after the conference.
IMUNON (NASDAQ: IMNN) presented promising new translational data from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study, involving 112 participants, demonstrated significant improvements in the tumor micro-environment (TME) through the local administration of IL-12 immunotherapy.
Key findings showed a positive TME shift in the majority of participants, with 50-80% of samples showing increased anti-tumor cells and 65-80% showing decreased immunosuppressive markers. The therapy effectively transformed "cold" tumors to "hot" by activating both innate and adaptive immune systems, while maintaining a favorable safety profile.
The company has initiated its pivotal Phase 3 OVATION 3 Study with four active trial sites currently enrolling patients.
IMUNON (NASDAQ: IMNN) announced it will present new translational data from its Phase 2 OVATION 2 Study of IMNN-001 at the AACR Special Conference in Cancer Research. IMNN-001 is a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer currently in Phase 3 development.
The therapy utilizes IMUNON's TheraPlas® technology platform, incorporating an IL-12 DNA plasmid vector into a nanoparticle delivery system. It has demonstrated clinical effectiveness in advanced ovarian cancer, showing benefits in both progression-free survival and overall survival when combined with standard chemotherapy.
The presentation, titled "IMNN-001, an IL-12 gene therapy, added to Neo/Adjuvant chemotherapy safely turns the tumor microenvironment cold-to-hot in newly diagnosed epithelial ovarian cancer (EOC)," will be delivered by Dr. Douglas V. Faller, Chief Medical Officer, on September 20, 2025.
IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York.
The company will provide a pre-recorded presentation that will be available on demand starting September 5, 2025, at 7:00 a.m. ET. IMUNON's management team will conduct in-person one-on-one meetings with investors from September 8-10, 2025. The presentation webcast will remain accessible for 90 days through the company's website.